← Back to Search
Chiral 1,3,4-oxadiazol-2-ones As Highly Selective FAAH Inhibitors.
Jayendra Z Patel, T. Parkkari, Tuomo Laitinen, A. Kaczor, S. Saario, J. Savinainen, Dina Navia-Paldanius, Mariateresa Cipriano, J. Leppänen, I. Koshevoy, A. Poso, C. Fowler, J. Laitinen, T. Nevalainen
Published 2013 · Chemistry, Medicine
Download PDFAnalyze on Scholarcy
In the present study, identification of chiral 1,3,4-oxadiazol-2-ones as potent and selective FAAH inhibitors has been described. The separated enantiomers showed clear differences in the potency and selectivity toward both FAAH and MAGL. Additionally, the importance of the chirality on the inhibitory activity and selectivity was proven by the simplification approach by removing a methyl group at the 3-position of the 1,3,4-oxadiazol-2-one ring. The most potent compound of the series, the S-enantiomer of 3-(1-(4-isobutylphenyl)ethyl)-5-methoxy-1,3,4-oxadiazol-2(3H)-one (JZP-327A, 51), inhibited human recombinant FAAH (hrFAAH) in the low nanomolar range (IC50 = 11 nM), whereas its corresponding R-enantiomer 52 showed only moderate inhibition toward hrFAAH (IC50 = 0.24 μM). In contrast to hrFAAH, R-enantiomer 52 was more potent in inhibiting the activity of hrMAGL compared to S-enantiomer 51 (IC50 = 4.0 μM and 16% inhibition at 10 μM, respectively). The FAAH selectivity of the compound 51 over the supposed main off-targets, MAGL and COX, was found to be >900-fold. In addition, activity-based protein profiling (ABPP) indicated high selectivity over other serine hydrolases. Finally, the selected S-enantiomers 51, 53, and 55 were shown to be tight binding, slowly reversible inhibitors of the hrFAAH.
This paper references
Mechanistic and Pharmacological Characterization of PF-04457845: A Highly Potent and Selective Fatty Acid Amide Hydrolase Inhibitor That Reduces Inflammatory and Noninflammatory Pain
Kay Ahn (2011)
Design, synthesis, and structure–activity relationships of 1,3,4-oxadiazol-2(3H)-ones as novel FAAH inhibitors
L. Kiss (2011)
Overview of the chemical families of fatty acid amide hydrolase and monoacylglycerol lipase inhibitors.
S. Vandevoorde (2008)
Chemical Probes of Endocannabinoid Metabolism
J. Blankman (2013)
Quantum mechanics/molecular mechanics modeling of fatty acid amide hydrolase reactivation distinguishes substrate from irreversible covalent inhibitors.
A. Lodola (2013)
Structure and function of fatty acid amide hydrolase.
M. K. McKinney (2005)
Dual blockade of FAAH and MAGL identifies behavioral processes regulated by endocannabinoid crosstalk in vivo
J. Z. Long (2009)
Application of computational methods to the design of fatty acid amide hydrolase (FAAH) inhibitors based on a carbamic template structure.
A. Lodola (2011)
Modulation of anxiety through blockade of anandamide hydrolysis
S. Kathuria (2003)
The discovery and development of inhibitors of fatty acid amide hydrolase (FAAH).
K. Otrubova (2011)
The endocannabinoid system as a target for novel anxiolytic and antidepressant drugs.
S. Gaetani (2009)
Discovery of boronic acids as novel and potent inhibitors of fatty acid amide hydrolase.
Anna Minkkilae (2008)
Biochemical and pharmacological characterization of human α/β-hydrolase domain containing 6 (ABHD6) and 12 (ABHD12)[S]
Dina Navia-Paldanius (2012)
Novel mechanistic class of fatty acid amide hydrolase inhibitors with remarkable selectivity.
K. Ahn (2007)
Discovery of PF-04457845: A Highly Potent, Orally Bioavailable, and Selective Urea FAAH Inhibitor.
D. S. Johnson (2011)
FAAH and MAGL inhibitors: therapeutic opportunities from regulating endocannabinoid levels.
S. Petrosino (2010)
Inhibition of anandamide hydrolysis by the enantiomers of ibuprofen, ketorolac, and flurbiprofen.
C. Fowler (1999)
A binding site for nonsteroidal anti-inflammatory drugs in fatty acid amide hydrolase.
Laura Bertolacci (2013)
NSAIDs: eNdocannabinoid stimulating anti-inflammatory drugs?
C. Fowler (2012)
Differential Sensitivity and Mechanism of Inhibition of COX-2 Oxygenation of Arachidonic Acid and 2-Arachidonoylglycerol by Ibuprofen and Mefenamic Acid†
J. J. Prusakiewicz (2009)
Inhibitors of the endocannabinoid-degrading enzymes, or how to increase endocannabinoid's activity by preventing their hydrolysis.
Marion Feledziak (2012)
Mechanism of inhibition of fatty acid amide hydrolase by sulfonamide-containing benzothiazoles: long residence time derived from increased kinetic barrier and not exclusively from thermodynamic potency.
G. Tian (2011)
Introduction to Structure, Mechanism, and Data Analysis, 2nd ed.
Z J. (2002)
Ibuprofen inhibits rat brain deamidation of anandamide at pharmacologically relevant concentrations. Mode of inhibition and structure-activity relationship.
C. Fowler (1997)
Cyclohexylcarbamic acid 3'- or 4'-substituted biphenyl-3-yl esters as fatty acid amide hydrolase inhibitors: synthesis, quantitative structure-activity relationships, and molecular modeling studies.
M. Mor (2004)
Acidic Nonsteroidal Anti-inflammatory Drugs Inhibit Rat Brain Fatty Acid Amide Hydrolase in a pH-dependent Manner
C. Fowler (2003)
Molecular Operating Environment (MOE), version 2012.10; Chemical Computing Group Inc
M. J. Frisch (2012)
Discovery of a potent, selective, and efficacious class of reversible alpha-ketoheterocycle inhibitors of fatty acid amide hydrolase effective as analgesics.
D. Boger (2005)
Fatty Acid Amide Hydrolase Inhibition Heightens Anandamide Signaling Without Producing Reinforcing Effects in Primates
Z. Justinova (2008)
VEGA – An open platform to develop chemo-bio-informatics applications, using plug-in architecture and script programming
A. Pedretti (2004)
Does the hydrolysis of 2-arachidonoylglycerol regulate its cellular uptake?
C. Fowler (2008)
Carrier‐mediated transport and enzymatic hydrolysis of the endogenous cannabinoid 2‐arachidonylglycerol
M. Beltramo (2000)
Inhibitors of fatty acid amide hydrolase (FAAH): SAR and results in pre-clinical pain models
J. Breitenbucher (2013)
A functional proteomic strategy to discover inhibitors for uncharacterized hydrolases.
W. Li (2007)
WinGX suite for small-molecule single-crystal crystallography
L. Farrugia (1999)
Discovery and development of fatty acid amide hydrolase (FAAH) inhibitors.
M. Seierstad (2008)
Tight-binding inhibitors-I. Kinetic behavior.
S. Cha (1975)
Aryl Piperazinyl Ureas as Inhibitors of Fatty Acid Amide Hydrolase (FAAH) in Rat, Dog, and Primate.
J. Keith (2012)
Brain monoglyceride lipase participating in endocannabinoid inactivation
T. V. Dinh (2002)
Anandamide Uptake Is Consistent with Rate-limited Diffusion and Is Regulated by the Degree of Its Hydrolysis by Fatty Acid Amide Hydrolase*
M. Kaczocha (2006)
Latest advances in the discovery of fatty acid amide hydrolase inhibitors
T. Bisogno (2013)
Exceptionally potent inhibitors of fatty acid amide hydrolase: the enzyme responsible for degradation of endogenous oleamide and anandamide.
D. Boger (2000)
Characterization of tunable piperidine and piperazine carbamates as inhibitors of endocannabinoid hydrolases.
J. Z. Long (2010)
Molecular characterization of an enzyme that degrades neuromodulatory fatty-acid amides
B. Cravatt (1996)
Use of an inhibitor to identify members of the hormone-sensitive lipase family.
Yassine Ben Ali (2006)
Fatty acid amide hydrolase inhibitors from virtual screening of the endocannabinoid system.
S. Saario (2006)
Screening of Various Hormone‐Sensitive Lipase Inhibitors as Endocannabinoid‐Hydrolyzing Enzyme Inhibitors
Anna Minkkilae (2009)
Reversible competitive α-ketoheterocycle inhibitors of fatty acid amide hydrolase containing additional conformational constraints in the acyl side chain: orally active, long-acting analgesics.
Cyrine Ezzili (2011)
Role of fatty acid amide hydrolase in the transport of the endogenous cannabinoid anandamide.
T. Day (2001)
(R)-Profens are substrate-selective inhibitors of endocannabinoid oxygenation by COX-2.
Kelsey C. Duggan (2011)
Inhibitory properties of ibuprofen and its amide analogues towards the hydrolysis and cyclooxygenation of the endocannabinoid anandamide
C. Fowler (2013)
Differential inhibition of prostaglandin endoperoxide synthase (cyclooxygenase) isozymes by aspirin and other non-steroidal anti-inflammatory drugs.
E. Meade (1993)
The PyMOL Molecular Graphics System, version 0.99; Schrödinger
M. W. Wong (2009)
Chemistry around imidazopyrazine and ibuprofen: discovery of novel fatty acid amide hydrolase (FAAH) inhibitors.
Frédéric De Wael (2010)
1,3,4-Oxadiazol-2-ones as fatty-acid amide hydrolase and monoacylglycerol lipase inhibitors: Synthesis, in vitro evaluation and insight into potency and selectivity determinants by molecular modelling.
Heikki Käsnänen (2013)
Inhibition of fatty acid amide hydrolase, a key endocannabinoid metabolizing enzyme, by analogues of ibuprofen and indomethacin.
S. Holt (2007)
Isolation and structure of a brain constituent that binds to the cannabinoid receptor.
W. Devane (1992)
Enzymes: A Practical Introduction to Structure, Mechanism, and Data Analysis
R. A. Copeland (1996)
Synthesis and evaluation of paracetamol esters as novel fatty acid amide hydrolase inhibitors.
V. Onnis (2010)
Structural Adaptations in a Membrane Enzyme That Terminates Endocannabinoid Signaling
M. Bracey (2002)
Synthesis and pharmacological evaluation of 2,4-dinitroaryldithiocarbamate derivatives as novel monoacylglycerol lipase inhibitors.
C. N. Kapanda (2012)
Biochemical and pharmacological characterization of human α / β - hydrolase domain containing 6 ( ABHD 6 ) and 12 ( ABHD 12 )
T. A. Day (2012)
Determination of absolute structure using Bayesian statistics on Bijvoet differences
Rob W.W. Hooft (2008)
Identification and characterization of carprofen as a multitarget fatty acid amide hydrolase/cyclooxygenase inhibitor.
Angelo D. Favia (2012)
Antidepressant-like activity and modulation of brain monoaminergic transmission by blockade of anandamide hydrolysis.
G. Gobbi (2005)
Piperazine and piperidine triazole ureas as ultrapotent and highly selective inhibitors of monoacylglycerol lipase.
Niina Aaltonen (2013)
The endocannabinoid system: a drug discovery perspective.
D. Piomelli (2005)
Highly selective inhibitors of monoacylglycerol lipase bearing a reactive group that is bioisosteric with endocannabinoid substrates.
J. Chang (2012)
Crystal structure of fatty acid amide hydrolase bound to the carbamate inhibitor URB597: discovery of a deacylating water molecule and insight into enzyme inactivation.
Mauro Mileni (2010)
A short history of SHELX.
G. Sheldrick (2008)
This paper is referenced by
Interaction of the N-(3-Methylpyridin-2-yl)amide Derivatives of Flurbiprofen and Ibuprofen with FAAH: Enantiomeric Selectivity and Binding Mode
Jessica Karlsson (2015)
A metal-free and mild approach to 1,3,4-oxadiazol-2(3H)-ones via oxidative C-C bond cleavage using molecular oxygen.
Bumhee Lim (2018)
Chemoproteomic, biochemical and pharmacological approaches in the discovery of inhibitors targeting human α/β-hydrolase domain containing 11 (ABHD11).
Dina Navia-Paldanius (2016)
N-Stearoyltyrosine protects primary cortical neurons against Aβ(1-40)-induced injury through inhibiting endocannabinoid degradation.
Hengjing Cui (2015)
4-Aryliden-2-methyloxazol-5(4H)-one as a new scaffold for selective reversible MAGL inhibitors
C. Granchi (2016)
Revisiting 1,3,4-Oxadiazol-2-ones: Utilization in the Development of ABHD6 Inhibitors.
Jayendra Z Patel (2015)
Inhibitors of Fatty Acid Amide Hydrolase and Monoacylglycerol Lipase: New Targets for Future Antidepressants
S. Ogawa (2015)
Application of N-Acylbenzotriazoles in the Synthesis of 5-Substituted 2-Ethoxy-1,3,4-oxadiazoles as Building Blocks toward 3,5-Disubstituted 1,3,4-Oxadiazol-2(3H)-ones.
Sirawit Wet-osot (2017)
Biochemical and Pharmacological Characterization of the Human Lymphocyte Antigen B-Associated Transcript 5 (BAT5/ABHD16A)
J. Savinainen (2014)
N-stearoyltyrosine protects primary cortical neurons against oxygen-glucose deprivation-induced apoptosis through inhibiting anandamide inactivation system
Heng-Jing Cui (2017)
Identification of selective covalent inhibitors of platelet activating factor acetylhydrolase 1B2 from the screening of an oxadiazolone-capped peptoid-azapeptoid hybrid library.
B. K. Sarma (2016)
A perspective review on fatty acid amide hydrolase (FAAH) inhibitors as potential therapeutic agents.
R. K. P. Tripathi (2019)
Synthesis, biological evaluation, and structure activity relationship (SAR) study of pyrrolidine amide derivatives as N-acylethanolamine acid amidase (NAAA) inhibitors.
Pan Zhou (2019)
Organocatalytic Enantioselective α‐Amination of Thiazol‐4‐one‐5‐carboxylates with Azodicarboxylates
Liying Cui (2018)
A New Use for an Old Drug: Carmofur Attenuates Lipopolysaccharide (LPS)-Induced Acute Lung Injury via Inhibition of FAAH and NAAA Activities
K. Wu (2019)
Solid phase synthesis of 1,3,4-oxadiazin-5 (6R)-one and 1,3,4-oxadiazol-2-one scaffolds from acyl hydrazides.
B. K. Sarma (2015)
Reversible Addition of Cyanide to Triphenylamine Attached Difluoroboron β‐Diketonate Facilitated Selective Colorimetric and Fluorimetric Detection of Cyanide ion
D. Tamilarasan (2020)
Discovery of Triterpenoids as Reversible Inhibitors of α/β-hydrolase Domain Containing 12 (ABHD12)
T. Parkkari (2014)
Synthesis and structure–activity relationships of ionizable 1,3,4-oxadiazol-2(3H)-ones as peripherally selective FAAH inhibitors with improved aqueous solubility
A. Beliaev (2016)
The fatty acid amide hydrolase and cyclooxygenase-inhibitory properties of novel amide derivatives of carprofen.
Alessandro Deplano (2020)
A Zn-MOF constructed from electron-rich π-conjugated ligands with an interpenetrated graphene-like net as an efficient nitroaromatic sensor
Y. Yang (2016)
The endocannabinoid system : a translational study from Achilles tendinosis to cyclooxygenase
Emmelie Björklund (2014)
Increased tonic cannabinoid CB1R activity and brain region-specific desensitization of CB1R Gi/o signaling axis in mice with global genetic knockout of monoacylglycerol lipase.
Dina Navia-Paldanius (2015)
Optimization of 1,2,5‐Thiadiazole Carbamates as Potent and Selective ABHD6 Inhibitors
Jayendra Z Patel (2015)
Monoacylglycerol lipase (MAGL) as a promising therapeutic target.
Ana Gil-Ordóñez (2018)
Cellular Activity of New Small Molecule Protein Arginine Deiminase 3 (PAD3) Inhibitors.
Haya Jamali (2016)
Therapeutic potential of targeting α/β-Hydrolase domain-containing 6 (ABHD6).
H. Deng (2020)
High-Resolution Confocal Fluorescence Imaging of Serine Hydrolase Activity in Cryosections – Application to Glioma Brain Unveils Activity Hotspots Originating from Tumor-Associated Neutrophils
Niina Aaltonen (2020)
Therapeutic Potential of Fatty Acid Amide Hydrolase, Monoacylglycerol Lipase, and N-Acylethanolamine Acid Amidase Inhibitors.
Wei Tuo (2017)